Changeflow GovPing Pharma & Drug Safety Inflazome Limited Novel Compounds Patent EP3759...
Routine Rule Added Final

Inflazome Limited Novel Compounds Patent EP3759102A1

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office has published patent application EP3759102A1 filed by Inflazome Limited. The application covers novel compounds (C07D class, pyrazole derivatives) with therapeutic applications including anti-inflammatory uses (A61P 29/00). The designated states include all EPO member states. This publication represents the grant of intellectual property rights covering specific molecular compositions.

What changed

The European Patent Office published patent application EP3759102A1 for Inflazome Limited, covering novel organic compounds (C07D subclasses) with therapeutic applications. The application designates all EPO member states including AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Competitors developing similar compounds in the anti-inflammatory or pharmaceutical space should review the patent claims for potential licensing needs or design-around strategies. National phase deadlines will apply for patent protection in individual member states.

What to do next

  1. Monitor patent database for national phase entry deadlines in relevant jurisdictions
  2. Evaluate freedom-to-operate for competing compounds

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL COMPOUNDS

Publication EP3759102A1 Kind: A1 Apr 08, 2026

Applicants

Inflazome Limited

Inventors

MILLER, David, VAN WILTENBURG, Jimmy, COOPER, Matthew

IPC Classifications

C07D 405/14 20060101AFI20190906BHEP C07D 231/18 20060101ALI20190906BHEP C07D 401/12 20060101ALI20190906BHEP C07D 405/04 20060101ALI20190906BHEP A61P 29/00 20060101ALI20190906BHEP A61K 31/415 20060101ALI20190906BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Rule
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3759102A1

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent prosecution IP licensing Drug development
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Medical Devices

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!